PAR-2 activation in CRC cells reduces doxorubicin-induced apoptosis by suppressing ROS generation and caspase-8/-3 activation, while upregulating anti-apoptotic proteins Mcl-1 and Bcl-xL via ERK1/2. This evidence concerns the gene MAPK3 and colorectal carcinoma.